雷公藤氯内酯醇抑制NLRP3炎症小体活化减轻Alzheimer病神经炎症反应
批准号:
81601116
项目类别:
青年科学基金项目
资助金额:
18.0 万元
负责人:
曾育琦
依托单位:
学科分类:
H0912.神经退行性变及相关疾病
结题年份:
2019
批准年份:
2016
项目状态:
已结题
项目参与者:
林楠、杨璐萌、陆剑平、林颖彬、许丹丹
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
阿尔茨海默病(AD)目前仍缺乏有效的治疗手段。神经炎症反应与AD病程的发生和发展密切相关,NLRP3炎症小体是AD神经炎症反应的重要环节。我们前期研究发现天然雷公藤减毒单体-雷公藤氯内酯醇(T4)可以提高AD转基因小鼠学习记忆功能,抑制胶质细胞活化和炎症介质生成,具有潜在防治AD作用,但其影响神经炎症的机制还有待于进一步探讨。为此我们提出假说:T4可能通过影响NF-κB核转位、抑制caspase-1和ASC活性、促进Aβ吞噬清除、抑制cathepsin B活性,最终影响NLRP3炎症小体活化,减轻神经炎症级联反应。为验证这一假说,我们以原代小胶质细胞、BV2细胞株和5XFAD APP/ PS1转基因小鼠为模型,采用western blot、real-time PCR、流式细胞术、慢病毒转染等手段,探讨T4影响NLRP3炎症小体的可能机制,为进一步应用T4防治AD提供客观的理论和实验依据。
英文摘要
There is still no effective treatment for Alzheimer's disease (AD). Neuroinflammation is key pathological change in the occurrence and development of AD. Furthermore, NLRP3 inflammasome is playing an important role in inflammation and tissue damage in AD. Our previous studies have found that Tripterygium extracts tripchlorolide T4, which has low toxicity and high pharmacological activity, can ameliorate cognitive deficits in 5XFAD APP/PS1 transgenic mice, glial cell activation and inflammatory mediators release. These results suggest that T4 may be a promising novel drug for AD, but its mechanism of anti-neuroinflammation in AD is still blurred. Depending on the previous investigations, we draw the hypothesis that T4 relieves neuroinflammation via affecting NLRP3 inflammasome activity. The NLRP3 activity is involved in NF-κB nuclear transfer, caspase 1, ASC activity, and cathepsin B activity, which is concerning about microglia up-taking and clearing Aβ. Additionally, the possible role of T4 in affecting NLRP3 inflammasome activity will be carried out in primary microglia culture, BV2 microglial cell line and 5XFAD APP/PS1 transgenic mice by western blot, real-time PCR, flow cytometry and lentivirus transfection. It will further confirm the effective treatment of T4 for AD in both theory and experiment.
专著列表
科研奖励列表
会议论文列表
专利列表
Cav3.1钙通道介导的Sphk/S1P信号在帕金森病模型中的作用及机制研究
- 批准号:82371265
- 项目类别:面上项目
- 资助金额:49万元
- 批准年份:2023
- 负责人:曾育琦
- 依托单位:
国内基金
海外基金















{{item.name}}会员


